Simulations to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL6 Antibody, for Treatment of Thyroid Eye Disease | サターラ

Simulations to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL6 Antibody, for Treatment of Thyroid Eye Disease

関連コンテンツ

How the US FDA MIDD paired pilot program helps sponsors

Combining mechanistic modeling with machine learning as a strategy to predict inflammatory bowel disease clinical scores

Behind the Science: A Conversation with Lamia Sid-Otmane

Driving Innovation in Pharmacometrics: An Interview with Wynand Smythe, Associate Director at Certara

Powered by Translations.com GlobalLink Web Software